Cancer clinical trials in the region Bourgogne-Franche-Comté
127 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
7 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
8 main criterias to confirm
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
8 main criterias to confirm
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
8 main criterias to confirm
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
7 main criterias to confirm
AstraZeneca
Phase 3
Kidney cancer
#NCT06364631
Clear cell carcinoma
Metastatic
None
0
1 or 2
Systemic Treatment-Naive
7 main criterias to confirm
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Hospitalier Universitaire de Besançon (Besançon)
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Rectal cancer
#NCT06762405
Adenocarcinoma
Localized
Locally Advanced
MSI/dMMR
None
Systemic Treatment-Naive
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Radiotherapy
Immunotherapy
Chemotherapy
Radiotherapy
9 main criterias to confirm
Centre hospitalier universitaire François Mitterrand (Dijon)
CHU Dijon
Phase 3
Lung cancer
#NCT06345729
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
KRAS G12C
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
Immunotherapy
9 main criterias to confirm
Centre hospitalier universitaire François Mitterrand (Dijon)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06472245
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Other mutation
Immunotherapy
ALK
EGFR
ROS-1
6 main criterias to confirm
Centre Hospitalier Universitaire de Besançon (Besançon)
OSE Immunotherapeutics